Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke
Status:
Terminated
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
The risk of recurrence is greatest immediately after stroke or Transient Ischaemic Attack
(TIA). Existing prevention strategies (antithrombotic, lipid/blood pressure lowering,
endarterectomy) reduce, not abolish, further events. Dual antiplatelet therapy - aspirin &
clopidogrel (AC) for IHD, aspirin & dipyridamole (AD) for stroke, is superior to aspirin
monotherapy. The investigators hypothesise that triple antiplatelet therapy (ACD) will be
superior to AD in patients at high-risk of recurrence, providing bleeding does not become
excessive.
Design: TARDIS is a multicentre, parallel-group, prospective, randomised, open-label,
blinded-endpoint, controlled trial. In the start-up phase, the investigators will assess over
3 years the safety, tolerability and feasibility of intensive therapy (ACD) versus guideline
therapy (AD) given for 1 month in 750 patients with acute stroke/TIA. The main phase will
then assess the safety and efficacy of ACD in up to 3500 patients. The primary outcome is
ordinal stroke (fatal/severe non-fatal/mild/TIA/none) at 90 days. Secondary outcomes include
death, MI, vascular events, function, bleeding, serious adverse events; sub-studies will
assess cerebral emboli and platelet function.